PF-Atlas › Clinical Trials › NCT02932566

The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

Pirfenidone · Phase 2

Registry ID
NCT02932566
Phase
Phase 2
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Manchester University NHS Foundation Trust
Start
2017-03-02
Enrollment
129
Locations
1

About this trial

This randomised, double-blind, placebo-controlled, phase 2 study aims to evaluate the efficacy and safety of the anti-fibrotic drug pirfenidone in the treatment of patients with heart failure and preserved left ventricular ejection fraction (HFpEF). Participants will be randomised to receive either pirfenidone or placebo, for a period of 12 months.

View NCT02932566 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT00287716
Medical disclaimer. This page summarizes public trial data for NCT02932566 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.